Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market

1. Grey Matters Health has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
3. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026

1. For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

The Alzheimer's disease diagnostics sector is experiencing strong expansion as demand rises for earlier and more precise identification of cognitive conditions. Market data indicate the space reached US$9.40 billion in 2025 and is projected to climb to US$26.21 billion by 2035, supported by the need for minimally invasive biomarker testing and imaging solutions.

According to a May report from Precendence Research on the Alzheimer's disease diagnostics market, the sector was valued at US$9.40 billion in 2025 and was projected to reach US$26.21 billion by 2035. Brain imaging already accounts for a sizable portion of activity, reflecting the growing reliance on tools that can reveal structural and amyloid changes associated with the disease.

Within this environment, Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) has taken concrete steps to build dedicated capacity. The company recently completed the first tranche of a non-brokered private placement, securing CA$500,000 through the issuance of 1,250,000 units priced at CA$0.40 each. Insider participation reached CA$184,000, conducted under applicable related-party guidelines that exempted the transaction from certain valuation and approval steps because values remained below the 25 percent market-capitalization threshold.

The closing of the first tranche of its previously announced non-brokered private placement financing. Cash finder's fees of CA$8,000 and 20,000 finder's warrants were also issued in connection with the tranche. The proceeds are earmarked for advancing the Alzheimer's program, including preparations for the company's initial U.S. brain-focused neuroimaging clinic, along with general corporate and working-capital needs.

Grey Matters has outlined a distinctive model centered on specialized positron emission tomography, or PET, imaging. PET is a nuclear-medicine technique that uses a small amount of radioactive tracer to visualize metabolic processes in tissue; when optimized for the brain, it can highlight early biological markers linked to Alzheimer's. The company intends to deploy this technology through a network of dedicated outpatient clinics rather than relying on general hospital radiology departments.

¹In a March 26 report, Stewart Thomson examined Grey Matters Health Inc.'s entry into the Alzheimer's disease diagnostics sector and described the company as "a Canadian healthcare company." The analyst highlighted the focus on early-stage detection using advanced, FDA-cleared brain-specific PET scanners and assigned technical price targets that have since been attained.

Artificial intelligence is simultaneously reshaping imaging workflows. The U.S. Food and Drug Administration had authorized 1,451 AI-enabled medical devices by the end of 2025, with radiology representing 76 percent of those clearances. Such tools assist in prioritizing scans, automating measurements, and supporting earlier identification of disease progression when applied to MRI and PET datasets.

The Imaging Wire reported in March that the U.S. Food and Drug Administration had authorized 1,451 AI-enabled medical devices through the end of 2025. Additional commentary noted that imaging volumes continue to rise due to aging populations and expanded screening, positioning AI as a meaningful aid for workflow efficiency and diagnostic support.

Additional commentary published by Becker's Hospital Review on May 18 described radiology as being at "a pivotal inflection point" as imaging volumes continued to increase across hospitals. Grey Matters plans to open its first NovaScan Neuroimaging Clinic in Davie, Florida, inside the HCA Florida University Medical Office Building. Roughly six million residents live within a one-hour drive, providing a sizable local population for services focused on Alzheimer's detection and related neurological conditions such as epilepsy and Parkinson's disease. 

According to the company's May 2026 presentation, the first NovaScan Neuroimaging Clinic is planned for Davie, Florida, at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus. The facility will employ the CareMiBrain PET system, an FDA-cleared brain-only scanner introduced in 2024 that operates without an accompanying CT component. Each clinic is expected to require approximately 1,750 square feet and roughly US$1.1 million in capital outlay for equipment and build-out. Catalyst MedTech is assisting with clinical and regulatory matters, American Molecular Imaging will provide radiology interpretation, and GE HealthCare Technologies will supply the Vizamyl F18-PET tracer for the Florida site. 

The financing remains available for additional closings expected on or before June 30, 2026, giving the company flexibility to accelerate clinic development.

Grey Matters said the offering remains open.

²Management and insiders hold approximately 11 percent of shares, while institutions own about 21 percent, with the balance held by retail investors. Leading holders include Alpha North Asset Management at 20.52 percent, Chief Executive Officer Christopher Moreau at 5.05 percent, Chairman Harry Bloomfield at 1.97 percent, Chief Financial Officer James Kinley at 1.4 percent, and Director Rajpaul Attariwala at 1.2 percent.

Grey Matters currently has 54.1 million shares outstanding, a market capitalization of US$1.37 million, and a 52-week trading range of US$0.035 to US$0.10.

By combining targeted financing with a focused clinic rollout and alignment with broader trends in early-detection imaging, Grey Matters Health is establishing a platform positioned to address rising clinical demand in the Alzheimer's diagnostics field.